Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ADH5 | P11766 | 4/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL611481 | 0.87 | CYP3A4 (1.00) | CYP3A4BAZ2BHTTMAPTADH5 | |
| Trifluoromethanesulfonic Acid SCHEMBL27843190 | 0.81 | CYP3A4 (0.66) | CYP3A4BAZ2BMAPTALDH1A1ADH5 | |
| Trifluoromethanesulfonic Acid SCHEMBL1524370 | 0.81 | CYP3A4 (0.66) | CYP3A4BAZ2BMAPTALDH1A1ADH5 | |
| SCHEMBL7868624 | 0.76 | CYP3A4 (0.58) | CYP3A4BAZ2BHTTMAPTNPC1 | |
| Benzaldehyde SCHEMBL27623570 | 0.76 | CYP3A4 (0.76) | CYP3A4BAZ2BHTTMAPTNPC1 | |
| Trifluoromethanesulfonic Acid SCHEMBL23277132 | 0.75 | CYP11B1 (0.71) | CYP3A4NPC1RAB9AMAOBKMT2A | |
| SCHEMBL10574724 | 0.74 | CYP3A4 (0.74) | CYP3A4BAZ2BHTTMAPTADH5 | |
| SCHEMBL13543203 | 0.74 | CYP3A4 (0.69) | CYP3A4BAZ2BHTTMAPTNPC1 | |
| SCHEMBL62049 | 0.73 | ADH5 (0.90) | CYP3A4BAZ2BHTTMAPTNPC1 | |
| SCHEMBL8591759 | 0.71 | CA1 (0.52) | CYP3A4BAZ2BHTTMAPTADH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658396-A1 | BELT REACTOR MANUFACTURING PROCESS FOR OLIGOMER SYNTHESIS | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4547683-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | Alnylam Pharmaceuticals, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240343746-A1 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | BANK OF AMERICA, N.A. | 2024-10-17 | — | — | US | disclosed |
| WO-2024163644-A1 | BELT REACTOR MANUFACTURING PROCESS FOR OLIGOMER SYNTHESIS | Arrowhead Pharmaceuticals, Inc. (US) | 2024-08-08 | — | — | WO | disclosed |
| WO-2024006999-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-4271696-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | Alnylam Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-116829567-A | Oligonucleotide prodrugs based on cyclic disulfide modified phosphates | 阿尔尼拉姆医药品有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2022147214-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343746-A1 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | RNGTT, TYMP, DCTPP1 | CYP3A4 4253/4885BAZ2B 3468/4885HTT 4811/4885 |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | CYP3A4 2590/4885BAZ2B 1680/4885HTT 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.